Population Health Research Institute
Study List

ONTARGET/TRANSCEND (Completed)
ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial
Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease

< back

 

A large, simple, randomized, double blind, multicentre, international trial comparing the effects of an Angiotensin II Receptor Antagonist (Temisartan), ACE-Inhibitor (Ramipril) and their combination on outcomes in patients at high risk for cardiovascular events.

Study Design: Randomized double-blind Parallel Group.

Intervention: Telmisartan and Ramipril vs. Placebo.

Length of Study: 6.5 years

# of Patients: 25,925

Patient Populations: High risk for cardiovascular events.


Parallel Trial




A large, simple randomized, double-blind, multicentre, international trial comparing the effects of an Angiotensin II Receptor Antagonist (Telmisartan) with placebo on outcomes in patients at high risk for cardiovascular events.

Study Design: Parallel Assignment.

Intervention: Telmisartan.

Length of Study: 6.5 years

# of Patients: 5,926

Patient Populations: High risk chronic stable cardiovascular or diabetes with end-organ damage.


Presentations

ONTARGET Final Results

TRANSCEND Final Results  

Main Publications (A full listing of publications can be found in the 'Media & Publictions' section)

The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.

Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-53.

The Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83.

The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004;48:52. 

Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K, on behalf of the ONTARGET/TRANSCEND Investigators.  Glucose levels predict hospitalization for congestive heart failure in patients with high cardiovascular risk. Circulation 2007;115:1371-1375.

Bohm M, Buamhakel M, Probstfield JL, Schmeider R, Yusuf S, Zhao F, Teo K. on behalf of the ONTARGET/TRANSCEND ED-Investigators.  Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: Substudy of the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmenNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). Am Heart J 2007;154:94-101. 

The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.

Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Matsarinne K, Parkhomenko A, Piegas LS, Svendsen TL, Oto A, Teo KK, Yusuf S, on behalf of the ONTARGET Investigators. Renal Outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET STUDY): a multicentre, randomized, double-blind, controlled trial. Lancet 2008;372:547-553. 

The TRANSCEND Investigators. Effects of the angiotensin receptor blocker, telmisartan on cardiovascular events in high-risk patients intolerant to ACE-inhibitors: a randomized controlled trial. Lancet 2008;372:1174-1183. 

Cowan BR, Young AA, Anderson C, Doughty RN, Krittayaphong R, Lonn E, Marwick TH, Reid CM, Sanderson JE, Schmieder RE, Teo K, Wadham AK, Worthley SG, Yu CM, Yusuf S, Jenning GL.  The cardiac MRI substudy to Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomdomzied Assessment Study in ACE-Intolerant Subjects with cardiovascular Disease: analysis protocol and baseline characteristics. Clin Res Cardiol 2009; 98:421-433. 

Mann JF, Schmeider RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Ryden L, Yu CM, Teo KK, Yusuf S for the TRANSCEND (Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009;151:1-10.

Sleight P, Redon J, Verdecchia, mancia G, Gao P, Fagard R, Schumacher H, Weber M, Bohm M, Williams B, Pogue J, Teo K, Yusuf S on behalf of the ONTARGET Investigators.  Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009;27:1360-1369.

(Back to top)

Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca